Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KIN101 (3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene) 是 IRF-3 依赖性信号传导的异黄酮激动剂,可诱导 IRF-3 核易位。 它对 RNA 病毒、HCV 和 RSV 具有抗病毒活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 218 | 现货 | ||
5 mg | ¥ 487 | 现货 | ||
10 mg | ¥ 747 | 现货 | ||
25 mg | ¥ 1,320 | 现货 | ||
50 mg | ¥ 2,160 | 现货 | ||
100 mg | ¥ 3,230 | 现货 | ||
200 mg | ¥ 4,630 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 现货 |
产品描述 | KIN101 (3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene), an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has antiviral activity against RNA viruses, HCV, and RSV. |
靶点活性 | DNV:>5 μM , Influenza virus:2 μM |
体外活性 | KIN101 results in a significant increase in the levels of ISGs as well as other proteins downstream of IRF activation such as RIG-I and MDA5[1].KIN101 (10 μM; 24 hours) causes a significant decrease in the NP protein abundance[1]. KIN 101 (10 μM; 18 hours) shows a >1 log decrease in HCV RNA levels. KIN 101 (5, 10, 20, 50 μM; 4 hours) causes a dose-dependent decrease in influenza virus infection in MRC5 cells[1]. KIN101 (0.01, 0.1, 1, 10, 100 μM) has a significant and dose-dependent effect on the formation of foci and has an IC50 of 0.2 μM[1]. |
别名 | 3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene, 3-(4-溴苯基)-4-氧代-7-[(甲磺酰基)氧基]-4H-色烯 |
分子量 | 395.22 |
分子式 | C16H11BrO5S |
CAS No. | 610753-87-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32 mg/mL (80.97 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5302 mL | 12.6512 mL | 25.3024 mL | 63.2559 mL |
5 mM | 0.506 mL | 2.5302 mL | 5.0605 mL | 12.6512 mL | |
10 mM | 0.253 mL | 1.2651 mL | 2.5302 mL | 6.3256 mL | |
20 mM | 0.1265 mL | 0.6326 mL | 1.2651 mL | 3.1628 mL | |
50 mM | 0.0506 mL | 0.253 mL | 0.506 mL | 1.2651 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KIN101 610753-87-2 Microbiology/Virology Proteases/Proteasome HCV Protease Influenza Virus RSV Antifection virus Isoflavone 3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene Hepatitis C virus Dengue hepatitis 3-(4-溴苯基)-4-氧代-7-[(甲磺酰基)氧基]-4H-色烯 HCV Inhibitor DNV Viral RNA broad-spectrum IRF-3 KIN 101 KIN-101 inhibit inhibitor